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A B S T R A C T
Background: Although smoking is a risk factor for cardiovascular diseases, little is known about the
impact of smoking on long-term outcomes in patients with atrial ﬁbrillation (AF).
Methods: In 426 consecutive patients with nonvalvular AF (mean age, 66 years; 307 men; mean follow-
up, 5.8  3.2 years), clinical variables including smoking status, CHADS2, and CHA2DS2-VASc score,
incidences of cardiovascular events (stroke, myocardial infarction, or admission for heart failure), bleeding,
and mortality were determined.
Results: Incidences of intracranial bleeding (0.7% vs 0.1%/year, p < 0.01), all-cause mortality (4.9% vs
2.6%/year, p < 0.01), and death from stroke (0.8% vs 0.2%/year, p < 0.05) were higher in patients with
history of smoking than in those without it. Incidence of intracranial bleeding was signiﬁcantly higher in
persistent smokers than in non-persistent smokers (1.2% vs 0.2%/year, p < 0.01). History of smoking
predicted all-cause mortality [hazard ratio (HR), 2.7; 95% conﬁdence interval (CI), 1.7–4.5; p < 0.01] and
death from stroke (HR 4.7; 95% CI 1.0–22.3; p < 0.05) independent of age, antithrombotic treatment,
CHADS2, and CHA2DS2-VASc score. Persistent smoking predicted intracranial bleeding (HR 4.4; 95% CI
1.1–17.6; p < 0.05) independent of age and antithrombotic treatment.
Conclusions: Smoking status, independent of age, antithrombotic treatment, and clinical risk factors,
predicted long-term adverse outcomes including bleeding events in patients with nonvalvular AF. There
might be an obvious impact of persistent smoking on intracranial bleeding.
 2014 Published by Elsevier Ltd on behalf of Japanese College of Cardiology.
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Balancing clinical beneﬁt of thromboprophylaxis by risk of
bleeding is the critical issue in anticoagulation treatment for
patients with atrial ﬁbrillation (AF) [1–5]. However, considerable
risk factors for stroke and thromboembolism in AF (e.g. aging,
history of stroke, hypertension, and renal dysfunction) [2–7] are
also risk factors for bleeding, and cardiovascular damage or
remodeling [8–12]. Cigarette smoking is a well known risk factor
for cardiovascular diseases including ischemic and hemorrhagic* Corresponding author at: Second Department of Internal Medicine, University
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0914-5087/ 2014 Published by Elsevier Ltd on behalf of Japanese College of Cardiolostrokes [13–16]. Smoking status relates to atherosclerosis [17],
vascular damage (e.g. endothelial dysfunction) [18,19], and AF
incidence [20,21] as well. In a recent study, a close relationship
between stroke and bleeding risk was shown [22]. Despite careful
risk assessment and management needed in patients with AF and
cardiovascular risks, little is known about the impact of smoking
on outcomes in AF patients. In the present study, we determined
the impact of smoking status on long-term outcomes in patients
with nonvalvular AF.
Methods
Study population
From November 1994 to May 2007, 745 patients with AF
underwent transesophageal echocardiography at Toyamagy.
K. Nakagawa et al. / Journal of Cardiology 65 (2015) 429–433430University Hospital. Of these, 526 patients with nonvalvular AF
gave written informed consent to participate in the follow-up
study. Four hundred and twenty-six patients with nonvalvular AF
in whom smoking status could be determined from their medical
records and follow-up questionnaires (307 men, mean age 66  11
years) constituted the study group. Patients in the acute phase of
infection or cardiovascular diseases including stroke, and those
receiving kidney transplant or hemodialysis were excluded. Chronic
AF was deﬁned as AF documented electrocardiographically on at least
two separate occasions (4 weeks apart). Baseline characteristics
including CHADS2 [Congestive heart failure, Hypertension, Age 75
years, Diabetes mellitus, Stroke (2 points)] [2], CHA2DS2-VASc
[Congestive heart failure, Hypertension, Age 75 years (2 points),
Diabetes mellitus, Stroke (2 points), Vascular disease, Age 65–74
years, Sex category (female)] [3] score, or HAS-BLED score (Hyper-
tension, Abnormal renal/liver function, Stroke, Bleeding history,
Labile international normalized ratio, Elderly, Drugs/alcohol) [9] for
each patient were obtained from medical records. Serial prothrombin
time-international normalized ratio (PT-INR) or liver function could
not be assessed; therefore, we used modiﬁed HAS-BLED (mHAS-
BLED) score (omitting labile INR and liver function). Smoking status
was classiﬁed as follows: positive versus negative history of smoking,
and persistent versus non-persistent smokers. Persistent smoking
was deﬁned if patients answered ‘‘yes’’ to the question ‘‘Do you
currently smoke?’’ at the end of follow-up or in the follow-up
questionnaires. Non-persistent smokers consisted of former smokers
and those who had never smoked. The point of PT levels we used was
at the entry of follow-up. The study was approved by the institutional
ethics committee at Toyama University Hospital, and informed
consent was obtained from each patient as indicated above.
Outcomes
The composite end points of all-cause death, stroke (ischemic
and hemorrhagic), cardiac events (myocardial infarction or
hospitalization for worsening of heart failure), and bleeding
(gastrointestinal and intracranial hemorrhages) were determined
in October 2008. Stroke and cardiac events constituted cardiovas-
cular events. Information on the end points was collected from
hospital databases and responses to questionnaires by patients
themselves or their family members. Ischemic stroke was deﬁnedTable 1
Clinical characteristics according to smoking status.
Overall 
n = 426 
Age (years) 66  11 
Men 307 (72) 
Chronic AF 204 (48) 
Heart failure 97 (23) 
Hypertension 162 (38) 
Age 75 years 101 (24) 
Diabetes mellitus 68 (16) 
Prior stroke/TIA 102 (24) 
CHADS2 score 1.5  1.4 
2 175 (41) 
CHA2DS2-VASc score 2.8  1.9 
2 314 (74) 
mHAS-BLED score 1.3  0.9 
Antiplatelet drugs 106 (25) 
Dual antiplatelet therapy 8 (2) 
Warfarin 319 (75) 
PT-INR 1.7  1.2 
Values are mean  SD or number (%) of patients.
AF, atrial ﬁbrillation; PT-INR, prothrombin time-international normalized ratio (determi
* Negative versus positive history of smoking.as a neurological deﬁcit of sudden onset, lasting >24 h and
conﬁrmed by brain computed tomography or magnetic resonance
imaging. Myocardial infarction was deﬁned as typical chest
symptoms with electrocardiographic changes and increases in
cardiac enzymes.
Statistical analyses
Data are expressed as mean  SD. All analyses were performed
using IBM SPSS Statistics (Version 20, IBM Corp., Chicago, IL, USA). The
mean values and proportion of variables were compared with
analysis of variance and x2 test, respectively. The outcomes were
displayed with Kaplan–Meier survival curves and compared with the
log-rank test. Cox proportional hazards regression was used to
determine independent predictors of the end points. A value of
p < 0.05 was considered statistically signiﬁcant.
Results
Baseline characteristics
Table 1 shows clinical characteristics according to smoking
status. Patients with a history of smoking were younger, populated
with a higher proportion of men and had lower CHA2DS2-VASc
score compared to those without history of smoking. Proportions
of warfarin and antiplatelet administration, or mean value of
mHAS-BLED score did not differ signiﬁcantly between the groups.
There were no patients with both warfarin and dual antiplatelet
therapy.
Outcomes
During a follow-up period of 5.8  3.2 years, 87 (20%) patients
died, 64 (15%) had cardiac events (6 myocardial infarction and
58 hospitalization for worsening of heart failure), 45 (11%) had stroke
(37 ischemic and 8 hemorrhagic), and 2 (0.5%) had gastrointestinal
bleeding. Table 2 shows causes of death. Long-term survival was
signiﬁcantly lower (71% vs 85%, p < 0.01), and there were more
deaths from malignancy (9% vs 3%, p < 0.01) in patients with history
of smoking than in those without it. There were 59 persistent
smokers. The incidences of intracranial bleeding, all-cause mortality,History of smoking p-value*
Negative Positive
n = 255 n = 171
68  12 65  11 <0.01
143 (56) 164 (96) <0.001
118 (46) 86 (50) 0.50
57 (22) 40 (23) 0.80
97 (38) 65 (38) 0.99
67 (26) 34 (20) 0.13
36 (14) 32 (19) 0.21
60 (24) 42 (25) 0.81
1.5  1.4 1.5  1.3 0.93
104 (41) 71 (42) 0.88
3.0  1.9 2.6  1.8 <0.05
195 (76) 119 (70) 0.12
1.3  0.9 1.2  1.0 0.24
55 (22) 51 (30) 0.10
4 (2) 4 (2) 0.57
195 (77) 124 (73) 0.33
1.8  1.4 1.6  0.8 0.40
ned in patients receiving warfarin); TIA, transient ischemic attack.
Table 2
Causes of death.
Smokers Men
Cardiovascular diseases 35 (40%) 18 23
Cardiac diseases 24 (28%) 10 14
Heart failure 20 (23%) 7 11
Myocardial infarction 4 (5%) 3 3
Stroke 11 (13%) 8 9
Ischemic 6 (7%) 3 4
Hemorrhagic 5 (6%) 5 5
Infection 12 (14%) 8 9
Malignancy 24 (28%) 16 21
Miscellaneous 16 (18%) 8 10
Percentages are based on total number of deaths.
Table 3
Event rates by smoking status.
Event rate (%/year) p-value*
History of smoking
Negative Positive
All-cause death 2.6 4.9 <0.01
Cardiovascular 1.2 1.8 0.19
Stroke (ischemic or hemorrhagic) 0.2 0.8 <0.05
Malignancy 0.5 1.6 <0.05
Myocardial infarction 0.1 0.4 0.08
Intracranial bleeding 0.1 0.7 <0.01
Event rate
(%/year)
p-value*
Persistent
smoking
No Yes
All-cause death 3.0 6.7 <0.01
Cardiovascular 1.3 2.4 0.10
Stroke (ischemic or hemorrhagic) 0.3 1.2 <0.01
Malignancy 0.7 2.7 <0.001
Myocardial infarction 0.2 0.3 0.65
Intracranial bleeding 0.2 1.2 <0.01
* Log-rank p-value for negative versus positive history of smoking (upper panel),
and non-persistent versus persistent smoking (lower panel).
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with history of smoking than in those without it (Table 3). In
persistent smokers, the incidence of intracranial bleeding (Fig. 2), all-
cause mortality, and death from stroke or malignancy was
signiﬁcantly higher and cardiovascular death tended to be higher
than in those of non-persistent smokers (Table 3). Patients who
developed intracranial bleeding were all men and had a higher
proportion of hypertension (75% vs 37%, p < 0.05), and CHADS2 score
2 (75% vs 40%, p < 0.05) compared to those without intracranial
bleeding. History of smoking, independent of age, antithrombotic
treatment, and CHADS2 and CHA2DS2-VASc score, predicted all-cause
mortality [hazard ratio (HR), 2.7; 95% conﬁdence interval (CI),
1.7–4.5; p < 0.01], death from stroke (HR 4.7; 95% CI 1.0–22.3;
p < 0.05), or death from malignant diseases (HR 2.8; 95% CI 1.1–7.2;
p < 0.05). Persistent smoking, independent of age or antithrombotic
treatment, predicted intracranial bleeding (HR 4.4; 95% CI 1.1–17.6;
p < 0.05).
Discussion
Major ﬁndings of the present study were as follows. First, the
incidence of stroke death was signiﬁcantly higher in patients with
a history of smoking than in those without it. Second, the incidence
of intracranial bleeding was signiﬁcantly higher in persistent
smokers than in non-persistent smokers. Persistent smoking
predicted intracranial bleeding independent of age or antithrom-
botic treatment.
Because risk factors for stroke are also risk factors for bleeding
in patients with AF [9], careful risk assessment and managementFig. 1. Kaplan–Meier curves for survival free from death from stroke by smoking
status (positive vs negative history of smoking).are crucial to balance efﬁcacy by safety of the treatment in these
patients. Cigarette smoking is also a well known cardiovascular
risk factor which relates to atherosclerosis [17], vascular damage
(e.g. endothelial dysfunction) [18,19] and incidence of AF [20,21].
Although mechanisms for smoking-related cardiovascular diseases
have not been fully elucidated, inﬂammation, oxidative stress
including lipid peroxidation, endothelial dysfunction, and hemo-
static and coagulation disturbances could contribute to smoking-
induced arterial tissue damage such as atherosclerosis and
structural wall damage/vulnerability [23,24]. In the present study,
the incidences of stroke death and intracranial bleeding both
related to smoking status; that is, positive versus negative history
of smoking or persistent versus non-persistent smoking. Acute
(e.g. activation and release of inﬂammatory cells, increase in acute
phase protein or proinﬂammatory cytokines, and hemostatic and
coagulation disturbances) and chronic (e.g. damage of artery wall)
effects of smoking [23,24] could contribute to structural weaknessFig. 2. Kaplan–Meier curves for survival free from intracranial bleeding by smoking
status (persistent vs non-persistent smokers).
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ischemic and hemorrhagic strokes. In a recent study, improvement
of endothelial function after smoking cessation was shown [25],
suggesting that persistence of smoking might relate to poor
outcomes, at least in part, through endothelial damage. Another
long-term follow-up study showed that the beneﬁt of quitting
smoking on risk of stroke was greater in hypertensive patients than
in normotensive subjects [26]. Moreover, NIPPON DATA 80 showed
that associations between smoking and stroke risk could be only
evident in populations with higher serum cholesterol levels [14],
and changes in lifestyle in Japanese (e.g. increase in fat
consumption) might explain an increase of adverse events in
recent populations having more cardiovascular risk factors. Taken
together, the relation of smoking with adverse cardiovascular
events is more evident in patients having cardiovascular risks (e.g.
AF, hypertension, hypercholesterolemia, and others).
Current schemes to predict bleeding risk in AF patients do not
include cigarette smoking as an independent predictor for bleeding
events [8,9], while persistent smoking independently predicted
intracranial bleeding in the present study. Indeed, the incidence of
intracranial and gastrointestinal bleeding was 0.3% and 1.2%/year
(non-persistent and persistent smokers, respectively) in the
present study, indicating that persistent smoking could be a risk
factor for bleeding in patients with AF. The present study consisted
of patients with relatively long-term follow-up period of 5.8 years
compared to previous studies [1 year in the National Registry of
Atrial Fibrillation (NRAF) [8] and the Euro Heart Survey [9], and
median 3.5 years in the Anticoagulation and Risk Factors in Atrial
Fibrillation (ATRIA) [10]]; this difference of follow-up period could
reveal the signiﬁcance of persistent smoking for the risk of
intracranial bleeding. Effects of lifestyle factors, such as smoking,
exercise and nutrition on vascular damage, are mostly indirect and
go through multiple paths, and therefore may take a certain length
of time. Chronic effects of persistent smoking thus might emerge as
a predictor for intracranial bleeding in the present study with a
longer follow-up period. High risk nature for cardiovascular and
non-cardiovascular death, and other cardiovascular events than
intracranial bleeding in AF patients with bleeding risks (e.g.
elderly, cardiovascular comorbidities), and the small number of
intracranial bleeding events may also explain that follow-up
duration could affect the outcomes. Accordingly, more compre-
hensive assessment of bleeding risk would be needed particularly
in patients with AF at high stroke/bleeding risk.
The present study had several limitations. First, the small
sample size from a single institution might have affected the
signiﬁcance of differences. Second, we did not quantify the number
of cigarettes in smokers or exposure to environmental tobacco
smoke. Measurement of serum, salivary, or urinary cotinine could
help to understand the effect especially of second-hand smoking
on the outcomes. Third, we did not evaluate serial prothrombin
time or time in therapeutic range during follow-up. We neither
evaluated changes of other medications, e.g. beta-blocker,
angiotensin receptor blocker or angiotensin-converting enzyme
inhibitor, during follow-up. We could obtain data on the use of
these drugs at the end of the study in about a third of our patients,
but not in all. The proportion of patients with beta-blockers was
42% and that of angiotensin receptor blocker or angiotensin-
converting enzyme inhibitor was 29%, and there were no
signiﬁcant differences between patients with and without history
of smoking. Fourth, the retrospective nature of the present study
and only using questionnaire could underestimate the event rates.
Although limited for these reasons, the present study indicates that
smoking status, independent of age, antithrombotic treatment, or
clinical risk factors, predicted long-term adverse outcomes
including bleeding events in patients with nonvalvular AF. Theremight be an impact of persistent smoking on intracranial bleeding
in these patients.
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